Business Description
XBiotech Inc
NAICS : 325410
SIC : 3741
ISIN : CA98400H1029
Total Employee Number:
87Description
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.97 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -10.9 | |||||
3-Year EPS without NRI Growth Rate | -16.8 | |||||
3-Year FCF Growth Rate | -37.6 | |||||
3-Year Book Growth Rate | -16.5 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 36.18 | |||||
9-Day RSI | 43.32 | |||||
14-Day RSI | 46.26 | |||||
3-1 Month Momentum % | 1.23 | |||||
6-1 Month Momentum % | -7.66 | |||||
12-1 Month Momentum % | -22.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 39.03 | |||||
Quick Ratio | 39.03 | |||||
Cash Ratio | 38.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -25.41 | |||||
ROA % | -24.4 | |||||
ROIC % | -197.53 | |||||
3-Year ROIIC % | -1403.08 | |||||
ROC (Joel Greenblatt) % | -170.01 | |||||
ROCE % | -24.97 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shiller PE Ratio | 2.15 | |||||
PB Ratio | 0.52 | |||||
Price-to-Tangible-Book | 0.52 | |||||
EV-to-EBIT | 2.31 | |||||
EV-to-EBITDA | 2.41 | |||||
EV-to-FCF | 2.18 | |||||
Price-to-GF-Value | 13.33 | |||||
| Price-to-Net-Current-Asset-Value | 0.63 | |||||
| Price-to-Net-Cash | 0.63 | |||||
Earnings Yield (Greenblatt) % | 43.29 | |||||
FCF Yield % | -60.41 |
XBiotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
XBiotech Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 122 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 31 days | ||
| General meeting for 2026 | 2026-07-24 | In 11 days | ||
| First quarter earnings results for 2026 | 2026-05-14 | 2.08 (-0.95%) | ||
| Annual report for 2025 | 2026-03-13 | 2.00 (+0.50%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 2.24 (+6.67%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 2.52 (+0.00%) | ||
| General meeting for 2025 | 2025-06-20 10:00 | 2.22 (-0.89%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 2.58 (+0.00%) | ||
| Annual report for 2024 | 2025-03-18 | 2.94 (+0.00%) |
Show
Entries
Press Release
Articles on XBiotech Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers